Pallas Health review

Start with what this is not, because it is the only thing that decides whether the rest matters to you: Pallas sells full-dose compounded semaglutide and full-dose compounded tirzepatide, and nothing underneath them. There is no low-dose product, no microdose tier and no dose selector anywhere before you pay, so starting small here means asking for less inside a full-dose plan and being billed the full-dose plan's price. If paying less for less is the whole reason you are shopping, this is a walk-past, and none of the rest changes it. The second thing to understand is the billing, because the advertised monthly figure is not a monthly figure — it is a twelve-week prepay divided by three, and no month-to-month option is published for either molecule. The shape catches people rather than the size: a small introductory payment, then the full quarterly charge in one go four weeks later. And twelve weeks is not three months, so a renewal anchored to an eighty-four-day cycle comes round more often in a year than dividing by three implies, which leaves the advertised average an understatement of what the plan costs to hold. What Pallas then does better than almost anything else here is prove who it is. It names six dispensing pharmacies outright and explains the difference between the two pharmacy categories, where the norm here is to name none. It names two prescribing clinicians with their registry numbers and links the federal registry so you can check them yourself. The price the marketing quotes is the price the checkout charges, cancellation is self-serve with a reminder before each renewal and no minimum term, and a clinician turning you down refunds you in full. Its FAQ also promises that the price does not climb as the dose does, which is exactly the commitment a low-dose reader wants in writing — but with no dose selector before purchase, you cannot test that promise before you pay. The promise is theirs to keep, and nothing on the site lets you check it in advance.

Vs median

$24/mo above the $175 median across the 299 of 548 programs here that publish a plain monthly rate

Market

$59–$1,300/mo is the full published spread on this site

Structure

Standard plan, self-directed low dose

Consult

Included in the price

Dietitian

Not confirmed

Labs

Optional

Pricing

Check plan terms

Pallas Health says it uses an unnamed partner network, but does not say which one. Bloodwork is offered but not required. A clinician review is included in the price.

Pallas Health is operated by Brentmoor, Inc. of Newark, Delaware, with clinical care delivered by Lion MD — a nationwide team of US-licensed clinicians — on the CareValidate clinical-operations platform. Pallas states plainly that it is a technology platform and does not employ medical providers. An online intake is reviewed asynchronously in 43 states; seven states (Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota and West Virginia) plus Washington DC require one video visit. It prescribes in all 50 states and DC, cash-pay only and never through insurance, with free shipping once a prescription is written. The catalog a buyer can actually reach is narrow: full-dose compounded semaglutide and full-dose compounded tirzepatide as weekly injections, alongside a brand-name pathway, and no low-dose or microdose product of any kind is purchasable through the funnel. Billing is the thing to understand before comparing this with anything else here — an introductory first period, then a single prepaid charge recurring every twelve weeks and anchored four weeks after approval, with the advertised monthly figure being that quarterly charge divided by three rather than a rate anyone is billed. The checkout is genuinely instrumented: Stripe Elements, Klarna pay-over-time, a promo-code field, a shipping-state eligibility guard, a self-serve cancellation portal, a pre-renewal email reminder, no minimum term, cancellation free and effective at the end of the current billing period, at least 30 days' notice before any price change, and a full refund if a clinician declines you.

There is no purchasable low-dose or microdose tier here — not on any screen, at any rung, by any path that was walked — and no dose selector appears anywhere before purchase. Pallas sells full-dose compounded semaglutide and full-dose compounded tirzepatide and nothing beneath them, so starting small means asking for less inside a full-dose plan and paying the full-dose plan's price

• The advertised "/mo average" is a twelve-week prepay divided by three, not a rate anyone is billed: there is no month-to-month rung for either molecule, and the funnel renders no cadence selector at all. The likeliest bill shock is the shape rather than the size — a $139 first payment, then $597 in one go four weeks later
• Twelve weeks is not three months. The renewal recurs every 84 days, which is 4.35 times a year rather than 4, while the advertised average divides by 3 — so on the company's own published terms the advertised figure understates the ongoing rate by about 8.7%
• The flat-price-at-every-dose promise could not be tested, because there is no pre-purchase dose selector to test it with — the one commitment that would matter most to a low-dose reader rests here on the company's word alone
• One of the six named dispensing pharmacies, Belmar, received an FDA warning letter over compounding practices, issued 03/31/2023 and addressed to "Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy" — FDA closed that letter out on 10/30/2023. Pallas itself carries no warning letter
• Only two clinicians are named site-wide. The prescribing network itself — Lion MD's affiliated professional corporations — is not published, and the footer's "Provider directory" link resolves to a section naming the same two people
• The site's own footer states that some of its content is AI-generated and makes no representation as to its accuracy, so its blog is not a source to take a clinical claim from; the advertised 4.8 rating has no published source; and the before-and-after "Verified Customer" stories carry the caveat that individuals shown in marketing may be actors or models
• Two charges sit outside the headline figures: in the seven video-visit states and DC a $60 visit deposit may be retained if you neither attend nor reschedule and then abandon the intake (otherwise it is refunded in full and credited to your first order), and a $5 fee is deducted per refunded payment on purchases made on or after July 14, 2026 — never on clinician-declined or unfulfilled orders, which refund in full
• Whether baseline or follow-up lab work is included or charged on top is not published anywhere, and no Trustpilot or BBB record corroborates the company's own figures
• No insurance, ever — and its brand-name pathway runs $1,069–$1,349 a month, far above what an insured patient pays for the same drugs
• It launched on this affiliate network on 1 July 2026, so the public record behind all of the above is short
• Compounded GLP-1s are not FDA-approved and are not generic equivalents of the brand drugs, and intentional microdosing is off-label and unproven — Pallas discloses the first properly, and the second is moot here because it sells no microdose

Pallas Health is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What the evidence actually shows
• What microdosing GLP-1 costs
• Titrating up from a microdose
• Microdose & reconstitution calculator
• Titration planner